Itrax (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in the synthesis of ergosterol, which is essential for fungal cell‑membrane integrity. By preventing ergosterol formation, the drug disrupts membrane structure, leading to increased permeability and inhibition of fungal growth.

The dosage of Itrax is individualized by the prescribing clinician based on the specific infection, severity, patient weight, renal and hepatic function, and other clinical factors. Healthcare professionals determine the appropriate regimen and duration according to current treatment guidelines.

Itrax is classified as pregnancy category C, indicating that risk to the fetus cannot be ruled out. It should only be used during pregnancy when the potential benefit justifies the potential risk. Limited data are available for breastfeeding; a decision should be made by the prescriber after weighing benefits and risks.

To order Itrax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with other azoles, itraconazole offers a broad spectrum that includes many molds and dimorphic fungi, and it has a high tissue penetration profile. Its pharmacokinetic profile differs, with a longer half‑life and the need for an acidic gastric environment for optimal absorption, which can influence choice over agents such as fluconazole or voriconazole.

Itrax should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Itrax is taken orally, usually as a tablet or capsule, and should be swallowed whole with a full glass of water. Depending on the formulation, it may be recommended to take it with food or on an empty stomach to improve absorption; patients should follow the prescribing information provided by their healthcare professional.

The most serious adverse events linked to Itrax include hepatotoxicity that can progress to severe liver injury, congestive heart failure or worsening of existing heart failure, QT‑interval prolongation leading to arrhythmias, and severe hypersensitivity reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these symptoms develop.

Itrax should be avoided in patients with known hypersensitivity to itraconazole or any azole antifungal, in those with severe hepatic impairment, uncontrolled heart failure, or in individuals taking contraindicated medications such as strong CYP3A4 inducers. Pregnant women should only use it when the potential benefit outweighs the risk, and it should be used with caution in breastfeeding mothers.